16 Participants Needed

A 16-Week Study of Pirenzepine or Placebo to Treat HIV-Associated Distal Sensory Polyneuropathy in Patients With HIV

Recruiting at 2 trial locations
AH
HK
DV
Overseen ByDaniel Vincent, M.Sc.
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: WinSanTor, Inc
Must be taking: Antiretrovirals
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a topical cream with pirenzepine for HIV patients who have nerve pain. The cream aims to reduce pain by blocking pain signals. The study will check if the cream is safe and effective over a few months.

Who Is on the Research Team?

AH

Angela Hansen

Principal Investigator

WinSanTor, Inc

Are You a Good Fit for This Trial?

Inclusion Criteria

Females should be either not of childbearing potential as a result of surgery or menopause (1 year after onset), or of childbearing potential and must be practicing a highly effective medically acceptable method of contraception, including abstinence; hormonal contraceptives (e.g., combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device or intrauterine system; or vasectomy (partner), for at least 1 month before the screening visit and for 1 month after the end of the last dose of study drug. If access or use of a highly effective medically acceptable method of contraception is not achievable, then a combination of barrier methods (e.g., male condom, female condom, cervical cap, diaphragm, contraceptive sponge) is acceptable. Eligible female subjects must also have a negative serum beta-human chorionic gonadotropin at the screening visit.
Return for study visits on the required dates
Prior week VAS for average pain/discomfort (altered sensation) and/or altered sensations on lower extremities > 20 mm and < 80mm (0 mm = no pain-100 mm = very severe pain) at screening.
See 16 more

Exclusion Criteria

You have skin or soft-tissue lesions on your calves, ankles, or tops of feet that are painful or could affect feeling.
Any open wound(s) and/or sunburn(s) in the dosing area. Subjects who have a wound and/or sunburn at screening that is anticipated to resolve before day -1 can be enrolled.
You have not taken any new or experimental drugs, biologics, or medical devices in the past 3 months before screening.
See 32 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks
1 visit (in-person)

Baseline

Baseline assessments and stratification based on pain scores using the Visual Analog Scale (VAS)

1 day
1 visit (in-person)

Treatment

Participants receive daily topical dosing of WST-057 or placebo for 16 weeks

16 weeks
Visits at Day 0, Weeks 4, 8, and 16

Follow-up

Participants are monitored for safety and effectiveness after treatment

2 weeks
1 visit (in-person) at Week 18

What Are the Treatments Tested in This Trial?

Interventions

  • WST-057
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Placebo Group
Group I: WST-057Experimental Treatment1 Intervention
WST-057 topical solution
Group II: PlaceboPlacebo Group2 Interventions
WST-057 Matching placebo

Find a Clinic Near You

Who Is Running the Clinical Trial?

WinSanTor, Inc

Lead Sponsor

Trials
4
Recruited
190+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security